UCB - Scientific research company
|UCB - Scientific research company|
|Type||Public / Private|
|Slogan||Inspired by patients.Driven by science.|
UCB (Union Chimique Belge) is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with a revenue of € 4.178 billion in 2016,which focuses primarily on research and development, specifically involving medications centered on epilepsy,Parkinson's, and Crohn's diseases.The Company's efforts are focused on treatments for severe diseases treated by specialists, particularly in the fields of central nervous system (CNS) disorders (including epilepsy), inflammatory disorders (including allergy), and oncology.
UCB is a global biopharmaceutical company, with a focus on neurology and immunology.
Our business is strong. Total revenue grew to €4.5 billion in 2017. We are more than 7,500 people in all four corners of the globe, inspired by patients and driven by science.
Looking ahead, we have a solid platform for continuous growth with our core products Cimzia®, Vimpat®, Neupro®, Keppra® and Briviact®, and we are preparing the launch of a potential medicine to help patients with osteoporosis. At the same time, we are very excited about the progress in our early research pipeline.
UCB’s ambition is to transform the lives of people living with severe diseases. We focus on neurology and immunology disorders – putting patients at the center of our world. We are Inspired by Patients. Driven by Science.
We listen. Our medicines treat thousands of people around the world and we are engaging with patients, their families and healthcare professionals to address their unmet needs.
We want to enhance our understanding of disease and the real-life experiences of patients so that our teams are able to deliver the right drug and the right care to the right patient.
UCB is continuously working to advance science and embrace new knowledge. We are leveraging scientific advances and skills in areas such as genetics, biomarkers and human biology. Patients inspire us to bring them value through cutting-edge science, innovative drugs, and practical solutions – so that they and their carers can get on with their lives.
We recognise that radical changes are taking place in the eco-system of care and that we need to evolve accordingly to deliver on our vision. The key element of our evolution is to focus on the delivery of increased patient value.
There is no such thing as an “average patient”. We want to use all the tools, channels and scientific advances at our disposal to develop a better understanding of the various expressions of a disease and embed the real needs of specific patient populations in our science and innovation process.
That is why we support patient groups who provide valuable services to patient communities and understand what matters to people living with severe diseases.
We believe in partnership. Our scientists collaborate with leading researchers from academia and industry to advance science and deliver the solutions patients need. Our open approach to innovation equips us to meet today’s biggest healthcare challenges.
UCB announces approval of VIMPAT® in China
- VIMPAT® (lacosamide) now approved in China as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in adult and adolescent patients 16 years of age and older with epilepsy.
- VIMPAT® will offer Chinese people living with epilepsy an additional treatment choice to support them in managing their disease.
- VIMPAT® approval reinforces and strengthens UCB’s leadership in epilepsy and the company’s ongoing commitment to supporting patient value creation across China
New approach accelerates drug discovery
Posted by Rafal Kaminski, Patient Value Unit - New Medicines 05-Sep-2018
- Researchers from Imperial College London, Singapore’s Duke-NUS Medical School, and UCB worked together to devise and validate a new computational method for drug discovery. This advanced framework known as CRAFT (Causal Reasoning Analytical Framework for Target discovery), has the potential to predict novel targets for future drugs.
- As proof-of-concept, the investigators applied their approach to epilepsy resulting in the discovery of a new drug target for epilepsy that was experimentally confirmed in pre-clinical models.
- The discovery and validation of this potential new anti-epileptic drug took less than two years – much faster than traditional approaches to medical research.
- It has the potential to transform medicine and improve lives by dramatically speeding up the identification of new drug targets across the spectrum of human disease.
- The team of scientists published their findings in Nature Communications, an international peer-reviewed publication.
- This research, funded by UCB, is an example of a successful international collaboration between academia and industry. It illustrates our commitment to partnership and to bringing together leading scientists to work together a common goal – improving the lives of patient
Top 5 Recent Tweets
|June 01, 2022||ucb_news||Today is the first day of #EULAR2022! We caught up with John Ioannou, Head of Global Medical Affairs, Rheumatology… https://t.co/3jrHiJclPz|